In contrast, the SC treated group showed a significantly (p < 0.001) decreased expression of AR, PSA, and 5α-reductase type 2, along with the Fina and Saw groups, compared to the BPH group. This evidence concerns the gene PROS1 and benign prostatic hyperplasia.